New Delhi, April 27 -- Sun Pharmaceutical Industries Ltd announced Monday that it has signed a definitive agreement to acquire Organon & Co. for $14.00 per share in an all-cash transaction, valuing the US-based healthcare company at an enterprise valuation of $11.75 billion.

Shares of Sun Pharma jumped over 7 per cent to Rs 1,737.20 after the company disclosed information about the acquisition and it was the top gainer in the Nifty 50 index during Monday's trading session.

The acquisition will see Sun Pharma combine its portfolio with Organon's to create a stronger player in established brands and branded generics, while also marking its entry into biosimilars as a top-10 global player. The deal is expected to close in early 2027, subje...